Skip to Content
Merck
CN

SML2955

Mirodenafil dihydrochloride

≥98% (HPLC)

Synonym(s):

4-[[3-(5-Ethyl-4,5-dihydro-4-oxo-7-propyl-1H-pyrrolo[3,2-d]pyrimidin-2-yl)-4-propoxyphenyl]sulfonyl]-1-piperazineethanol, dihydrochloride, 5-Ethyl-2-[5-[[4-(2-hydroxyethyl)piperazin-1-yl]sulfonyl]-2-propoxyphenyl]-7-propyl-3,5-dihydro-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, 5-Ethyl-3,5-dihydro-2-[5-[[4-(2-hydroxyethyl)-1-piperazinyl]sulfonyl]-2-propoxyphenyl]-7-propyl-4H-pyrrolo[3,2-d]pyrimidin-4-one, dihydrochloride, SK 3530 dihydrochloride, SK-3530 dihydrochloride, SK3530 dihydrochloride

Sign In to View Organizational & Contract Pricing.

Select a Size

About This Item

Empirical Formula (Hill Notation):
C26H37N5O5S·2HCl
CAS Number:
862189-96-6
Molecular Weight:
604.59
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
MFCD28139019

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

SMILES string

[S](=O)(=O)(N4CCN(CC4)CCO)c1cc(c(cc1)OCCC)c2[nH][c](c3[n](cc(c3n2)CCC)CC)=O.Cl.Cl

InChI

1S/C26H37N5O5S.2ClH/c1-4-7-19-18-30(6-3)24-23(19)27-25(28-26(24)33)21-17-20(8-9-22(21)36-16-5-2)37(34,35)31-12-10-29(11-13-31)14-15-32;;/h8-9,17-18,32H,4-7,10-16H2,1-3H3,(H,27,28,33);2*1H

InChI key

CKPHITUXXABKDL-UHFFFAOYSA-N

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

−20°C

Quality Level

100

Related Categories

Biochem/physiol Actions

Mirodenafil (SK3530) is an orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor (IC50 = 338 pM). with therapeutic efficacy in various ED models in vivo. Comparing to sildenafil, mirodenafil shows ~10-times higher PDE5 selectivity in vitro and remains longer in the plasma and corpus cavernosum following oral dosing at 40 mg/kg in rats in vivo.
Orally active, highly potent and selective phosphodiesterase-5 (PDE5) inhibitor with ED therapeutic efficacy in vivo.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000119244
0000119448
0000106108

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Ji-Youn Jung et al.
The Journal of veterinary medical science, 70(11), 1199-1204 (2008-12-06)
Mirodenafil (SK3530) is a new potent and selective inhibitor of cGMP-specific phosphodiesterase type 5 (PDE5). Recent clinical trials have demonstrated that mirodenafil is an effective treatment for erectile dysfunction. Its mechanism of action is enhancement of nitric oxide (NO) induced
Ji Sung Shim et al.
Urology, 91, 244-244 (2016-02-28)
To evaluate the distribution of a daily phosphodiesterase type 5 inhibitor dose (mirodenafil) in rat plasma and bladder and prostate tissue in a model of atherosclerosis-induced chronic pelvic ischemia. Thirty-two 18-week-old male Sprague Dawley rats were divided into two groups.
Jae Heon Kim et al.
The world journal of men's health, 38(3), 345-352 (2019-08-07)
To validate a novel arteriogenic erectile dysfunction (ED) model with atherosclerosis (AS) based on molecular and histologic evidence induced by chronic pelvic ischemia (CPI) and determine effect of phosphodiesterase-5 inhibitor treatment. Twenty 16-week-old male Sprague-Dawley rats were divided into three
Hoon Choi et al.
International neurourology journal, 19(1), 19-26 (2015-04-04)
To investigate the protective effect of mirodenafil on bladder function in a rat model of chronic bladder ischemia (CBI). Twenty-four Sprague-Dawley rats were randomized to three groups: untreated, sham-operated rats (control group); untreated, CBI model rats (CBI group); and CBI
Young H Choi et al.
Biopharmaceutics & drug disposition, 30(6), 305-317 (2009-07-30)
The pharmacokinetics of mirodenafil and its two metabolites, SK3541 and SK3544, after intravenous (5, 10, 20 and 50 mg/kg) and oral (10, 20 and 50 mg/kg) administration of mirodenafil, and the first-pass effect of mirodenafil after intravenous, oral, intraportal, intragastric
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service